Methods for Enhancing Bacterial Cell Display of Proteins and Peptides

• US 20180002687A1
• Filed: 06/05/2017
• Published: 01/04/2018
• Est. Priority Date: 07/26/2007
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Daugherty, Patrick Sean, Rice, Jeffrey
• Granted Patent: US 10,640,762 B2
• Time in Patent Office: Days
• CPC Class Codes: C07K 14/195 from bacteria
• CPC Class Codes: C07K 14/245 Escherichia (G)
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00
• CPC Class Codes: C12N 15/1037 Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Abstract

Methods of making and using bacterial display polypeptide libraries using circularly permuted OmpX (CPX) variants are disclosed. The invention further relates to methods for enhancing the display of proteins and peptides at the surface of bacteria by optimizing linkers and incorporating mutations at positions 165 and 166 of CPX.

Claims

1-42. -42. (canceled)

43. A circularly permuted OmpX (CPX) variant comprising

a linker joining the native N-terminus and native C-terminus of OmpX,

wherein the CPX variant comprises a non-native N-terminus and a non-native C-terminus,

wherein the linker is 4-8 residues in length and comprises a sequence X-Z_n,

wherein X is an amino acid selected from the group consisting of:

serine, threonine, and proline,

wherein each Z is independently any amino acid, and n is 2 to 4, and

wherein at least one of the Z residues is independently selected from the group consisting of;

lysine, arginine, glutamine, asparagine, or histidine.

44. The CPX variant of claim 43, wherein the first residue of the linker is a glycine.

45. The CPX variant of claim 43, wherein the linker comprises at least two basic residues.

46. The CPX variant of claim 43, wherein the linker comprises two arginine residues.

47. The CPX variant of claim 43, wherein the linker comprises two lysine residues.

48. The CPX variant of claim 43, wherein the linker comprises at least one arginine residue and at least one lysine residue.

49. The CPX variant of claim 43, wherein the linker is 5 residues in length.

50. The CPX variant of claim 43, wherein the linker is 6 residues in length.

51. The CPX variant of claim 50, wherein the first residue of the linker is a glycine and the third and sixth residues of the linker are selected from the group consisting of arginine, lysine, serine, histidine, glutamine, and asparagine.

52. The CPX variant of claim 43, comprising one or more mutations that increase the display efficiency of a passenger peptide compared to the CPX variant in the absence of the mutations, wherein at least one mutation is at a position corresponding to A165 or G166 of the native OmpX protein consisting of SEQ ID NO:

1.

53. The CPX variant of claim 52, comprising one or more mutations selected from the group consisting of an A165V mutation, an A165L mutation, an A165I mutation, an A165F mutation, a G166S mutation, a G166A mutation and combinations thereof.

54. The CPX variant of claim 43, comprising a passenger polypeptide fused to the non-native N-terminus of the CPX variant.

55. The CPX variant of claim 54, comprising a linker between the non-native N-terminus of the CPX variant and the passenger polypeptide.

56. The CPX variant of claim 43, comprising a passenger polypeptide fused to the non-native C-terminus of the CPX variant.

57. The CPX variant of claim 56, comprising a linker between the non-native C-terminus of the CPX variant and the passenger polypeptide.

58. The CPX variant of claim 43, comprising a first passenger polypeptide fused to the non-native N-terminus of the CPX variant and a second passenger polypeptide fused to the non-native C-terminus of the CPX variant.

59. The CPX variant of claim 58, wherein the first passenger polypeptide or the second passenger polypeptide comprises a detectable label.

60. The CPX variant of claim 59, wherein both the first passenger polypeptide and the second passenger polypeptide comprise detectable labels.

61. The CPX variant of claim 60, wherein the first passenger polypeptide comprises a different detectable label than the second passenger polypeptide.

62. The CPX variant of claim 58, comprising a linker between the first passenger polypeptide and the non-native N-terminus of the CPX variant or the second passenger polypeptide and the non-native C-terminus of the CPX variant.

63. The CPX variant of claim 62, wherein the linker between the first passenger polypeptide and the non-native N-terminus of the CPX variant or between the second passenger polypeptide and the non-native C-terminus of the CPX variant comprises a sequence selected from the group consisting of SEQ ID NO:

28 and SEQ ID NO;

34.

64. A method of making a polypeptide display library, the method comprising:

providing a plurality of expression vectors expressing CPX variants of claim 43 carrying a plurality of passenger polypeptides;

transfecting bacterial cells with said expression vectors; and

culturing the bacterial cells under conditions that permit expression of said passenger polypeptides on the surface of the bacterial cells.

65. A method of screening for a CPX variant that displays a passenger polypeptide with greater efficiency than another carrier protein carrying the same passenger polypeptide, the method comprising:

transfecting a bacterial cell with an expression vector expressing a CPX variant of claim 43 carrying the passenger polypeptide;

screening for display of the passenger polypeptide at the surface of the bacterial cell within 25 minutes after inducing the expression of the CPX variant carrying the passenger polypeptide; and

comparing the display efficiency of the CPX variant carrying the passenger polypeptide to the display efficiency of another carrier protein carrying the same passenger polypeptide expressed under the same conditions.

66. A method of enhancing the display efficiency of a passenger polypeptide, the method comprising:

screening a plurality of different CPX variants of claim 43; and

selecting the CPX variant that displays the passenger polypeptide with the greatest efficiency compared to the plurality of other CPX variants.

67. A method of screening a library of polypeptides for the ability to bind to a target molecule, the method comprising:

a) providing a polypeptide display library comprising CPX variants of claim 43 carrying a plurality of passenger polypeptides displayed on bacterial cells,

b) contacting the plurality of passenger polypeptides with the target molecule, and

c) identifying at least one displayed passenger polypeptide that binds to the target molecule.

68. The method of claim 67, wherein the target molecule is selected from the group consisting of a receptor, a ligand, an antibody, an antigen, an enzyme, a transporter, a substrate, an inhibitor, an activator, a cofactor, a drug, a nucleic acid, a lipid, a carbohydrate, a glycoprotein, a small organic molecule, and an inorganic molecule.

69. The method of claim 67, wherein said target molecule comprises a detectable label, wherein identifying the target molecule bound to at least one passenger polypeptide comprises detecting the label attached to said target molecule.

70. A method of screening a library of polypeptides for biological activity in the presence of a target molecule, the method comprising:

a) providing a polypeptide display library comprising CPX variants of claim 43 carrying a plurality of passenger polypeptides displayed on bacterial cells,

b) contacting the plurality of passenger polypeptides with the target molecule,

c) assaying for biological activity in the presence of the target molecule, and

d) identifying at least one displayed passenger polypeptide that has biological activity.

71. The method of claim 70, wherein the biological activity is enzymatic activity, substrate activity, ligand-binding activity, transport activity, agonist activity, or antagonist activity.

72. The method of claim 70, wherein the target molecule is selected from the group consisting of a receptor, a ligand, an antibody, an antigen, an enzyme, a transporter, a substrate, an inhibitor, an activator, a cofactor, a drug, a nucleic acid, a lipid, a carbohydrate, a glycoprotein, a small organic molecule, and an inorganic molecule.

73. The CPX variant of claim 55, wherein the linker between the non-native N-terminus of the CPX variant and the passenger polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:

28 and SEQ ID NO;

34.

74. The CPX variant of claim 57, wherein the linker between the non-native C-terminus of the CPX variant and the passenger polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:

28 and SEQ ID NO;

34.

75. The CPX variant of claim 43, wherein 2 or 3 of the Z residues are independently selected from the group consisting of:

lysine, arginine, glutamine, asparagine, or histidine.

76. The CPX variant of claim 75, comprising one or more mutations that increase the display efficiency of a passenger peptide compared to the CPX variant in the absence of the mutations, wherein at least one mutation is at a position corresponding to A165 or G166 of the native OmpX protein consisting of SEQ ID NO:

1.

77. The CPX variant of claim 76, comprising one or more mutations selected from the group consisting of an A165V mutation, an A165L mutation, an A165I mutation, an A165F mutation, a G166S mutation, a G166A mutation and combinations thereof.

78. The CPX variant of claim 75, comprising a passenger polypeptide fused to the non-native N-terminus of the CPX variant.

79. The CPX variant of claim 78, comprising a linker between the non-native N-terminus of the CPX variant and the passenger polypeptide, wherein said linker comprises a sequence selected from the group consisting of SEQ ID NO:

28 and SEQ ID NO;

34.

80. The CPX variant of claim 75, comprising a passenger polypeptide fused to the non-native C-terminus of the CPX variant.

81. The CPX variant of claim 80, comprising a linker between the non-native C-terminus of the CPX variant and the passenger polypeptide, wherein said linker comprises a sequence selected from the group consisting of SEQ ID NO:

28 and SEQ ID NO;

34.